597 related articles for article (PubMed ID: 17306703)
1. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
[TBL] [Abstract][Full Text] [Related]
3. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
[TBL] [Abstract][Full Text] [Related]
4. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure.
Kourea K; Parissis JT; Farmakis D; Paraskevaidis I; Panou F; Filippatos G; Kremastinos DT
Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):365-9. PubMed ID: 18525396
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
6. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Parissis JT; Kourea K; Panou F; Farmakis D; Paraskevaidis I; Ikonomidis I; Filippatos G; Kremastinos DT
Am Heart J; 2008 Apr; 155(4):751.e1-7. PubMed ID: 18371487
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
[TBL] [Abstract][Full Text] [Related]
9. Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Parissis JT; Kourea K; Andreadou I; Ikonomidis I; Markantonis S; Ioannidis K; Paraskevaidis I; Iliodromitis E; Filippatos G; Kremastinos DT
Am J Cardiol; 2009 Apr; 103(8):1134-8. PubMed ID: 19361602
[TBL] [Abstract][Full Text] [Related]
10. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
11. Treatment of anemia with darbepoetin alfa in systolic heart failure.
Swedberg K; Young JB; Anand IS; Cheng S; Desai AS; Diaz R; Maggioni AP; McMurray JJ; O'Connor C; Pfeffer MA; Solomon SD; Sun Y; Tendera M; van Veldhuisen DJ; ;
N Engl J Med; 2013 Mar; 368(13):1210-9. PubMed ID: 23473338
[TBL] [Abstract][Full Text] [Related]
12. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
Gordon D; Nichols G; Ben-Jacob A; Tomita D; Lillie T; Miller C
Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
15. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
16. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
[TBL] [Abstract][Full Text] [Related]
17. Treatment of anemia with darbepoetin alfa in heart failure.
Abraham WT; Anand IS; Klapholz M; Ponikowski P; Scarlata D; Wasserman SM; van Veldhuisen DJ
Congest Heart Fail; 2010; 16(3):87-95. PubMed ID: 20557327
[TBL] [Abstract][Full Text] [Related]
18. Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.
Maurer MS; Teruya S; Chakraborty B; Helmke S; Mancini D
Circ Heart Fail; 2013 Mar; 6(2):254-63. PubMed ID: 23258574
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
[TBL] [Abstract][Full Text] [Related]
20. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]